Japan Alzheimer’s Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Product (Cholinesterase Inhibitors, NMDA Receptor Antagonist, Combination Drug, and Pipeline Drugs), By End User (Hospital Pharmacy, Retail Pharmacy, and E-commerce), and Japan Alzheimer’s Therapeutics Market Insights, Industry Trend, Forecasts to 2035

Japan Alzheimer’s Therapeutics Market Insights Forecasts to 2035

• The Japan Alzheimer’s Therapeutics Market Size Was Estimated at USD 563.2 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 18.63% from 2025 to 2035
• The Japan Alzheimer’s Therapeutics Market Size is Expected to Reach USD 3689.3 Million by 2035

According to a research report published by Spherical Insights & Consulting, the Japan Alzheimer’s Therapeutics market is anticipated to reach USD 3689.3 million by 2035, growing at a CAGR of 18.63% from 2025 to 2035. The Japan Alzheimer’s therapeutics market is driven by various factors, including rising prevalence of Alzheimer's disease, rise in aging population, rising awareness, early diagnosis initiatives, and ongoing R&D in novel therapies.

Market Overview

The Japan Alzheimer's therapeutics market focuses on the development and delivery of treatments for Alzheimer's disease. Alzheimer's disease is a neurological condition that develops over time and mostly impacts thinking, behavior, and memory. It is the most frequent cause of dementia in the geriatric population. The medication and treatment strategies used to treat Alzheimer's are referred to as Alzheimer's therapeutics. Japan is one of the highest aging population country and older adults are primarily affected by Alzheimer's disease is one of the key driving factors for this market. The market for Alzheimer's therapies is expanding owing to government funding for Alzheimer's research, treatment cost subsidies, and initiatives to enhance senior care. The rising demand for personalized medication is the key trend in this market. In the market for Alzheimer's treatments, the creation of biomarker-based diagnostics for the condition offers a significant opportunity for growth.

Report Coverage

This research report categorizes the market for the Japan Alzheimer’s therapeutics market based on various segments and regions, and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan Alzheimer’s therapeutics market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan Alzheimer’s therapeutics market.

Driving Factors

Japan's rapidly aging population is a major driver of the country's Alzheimer's therapeutics market, as it raises the prevalence of Alzheimer's disease and demands immediate care and effective treatment solutions. The emergence of specialist memory clinics, dementia care centres, and specialty sections within hospitals ensures that patients receive complete and specialized treatment. These facilities have been equipped with cutting-edge diagnostic tools and therapeutic resources, allowing for timely and accurate diagnosis and treatment. Government is taking initiatives by funding research and early diagnosis programs, which further boost the market growth. Additionally, the advances in diagnostic technologies play a crucial role in market expansion.

Restraining Factors

One of the significant challenges is the high cost of Alzheimer’s therapeutics, which limits the affordability and accessibility of treatments, particularly in low-income regions. There are strict regulations for Alzheimer's therapeutics led to the complexity and delay in product approval.

Market Segmentation

The Japan Alzheimer’s therapeutics market share is classified into product and end user.

• The cholinesterase inhibitors segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.    

The Japan Alzheimer’s therapeutics market is segmented by product into cholinesterase inhibitors, NMDA receptor antagonist, combination drug, and pipeline drugs. Among these, the cholinesterase inhibitors segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is because it is standard care for Alzheimer's treatment. Additionally, they are most effective in the early stages.

• The hospital pharmacy held the highest share in 2024 and is expected to grow at a substantial CAGR during the forecast period.    

The Japan Alzheimer’s therapeutics market is segmented by end user into hospital pharmacy, retail pharmacy, and e-commerce. Among these, the hospital pharmacy segment held the highest share in 2024 and is expected to grow at a substantial CAGR during the forecast period. This is due to a rise in hospitalizations due to a rise in the aging population and an increase in Alzheimer’s patients.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan Alzheimer’s therapeutics market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Eisai Co., Ltd
• Daiichi Sankyo Company, Limited
• Otsuka Holdings Co., Ltd.
• Astellas Pharma Inc
• Mitsubishi Tanabe Pharma Corporation
• Sumitomo Pharma Co., Ltd
• Takeda Pharmaceutical Company Limited
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Pfizer Inc.
• H. Lundbeck A/S
• Other

Recent Developments

• In May 2024, Japan’s Otsuka Pharmaceutical discontinued its Alzheimer’s drug AVP-786 after it failed to show significant results in treating agitation in late-stage trials.
• In September 2023, Japan approved Leqembi, an Alzheimer’s treatment by Eisai and Biogen. The drug targets amyloid beta plaques to slow early-stage Alzheimer’s progression.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan Alzheimer’s therapeutics market based on the below-mentioned segments:

Japan Alzheimer’s Therapeutics Market, By Product

• Cholinesterase inhibitors
• NMDA Receptor Antagonist
• Combination Drug
• Pipeline Drugs

Japan Alzheimer’s Therapeutics Market, By End user

• Hospital Pharmacy
• Retail Pharmacy
• E-commerce